Medicamen Biotech Limited (BOM:531146)

Medicamen Biotech Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Operating Revenue	1,627	1,603	1,779	1,404	1,083	1,107
Other Revenue	71.88	72.21	14.26	4.58	71.55	19.94
Revenue	1,699	1,675	1,793	1,409	1,154	1,127
Revenue Growth (YoY)	-6.43%	-6.56%	27.29%	22.02%	2.42%	-10.21%
Cost of Revenue	838.19	864.86	941.05	734.49	542.07	710.91
Gross Profit	861.18	810.61	852.01	674.19	612.38	416.25
Selling, General & Admin	367.93	353.42	335.17	218.24	155.56	95.99
Other Operating Expenses	294.89	268.61	293.34	215.96	220.16	126.81
Operating Expenses	726.29	692.69	699.44	497.86	433.43	248
Operating Income	134.89	117.92	152.57	176.32	178.96	168.25
Interest Expense	-35.52	-31.56	-43.97	-29.23	-14.01	-10.64
Interest & Investment Income	5.07	5.07	7.24	7.21	1.35	1.53
Currency Exchange Gain (Loss)	7.06	7.06	13.85	14.76	14.49	4.71
Other Non Operating Income (Expenses)	0.28	0.28	0.33	1.29	0.08	0.01
EBT Excluding Unusual Items	111.79	98.78	130.02	170.35	180.87	163.87
Gain (Loss) on Sale of Investments	-	-	-	-	0.02	0.04
Gain (Loss) on Sale of Assets	-	-	0	-0.07	-0.01	-0.01
Pretax Income	111.81	98.8	130.76	170.45	180.95	163.94
Income Tax Expense	26.81	33.24	35.82	23.17	31.97	42.65
Earnings From Continuing Operations	85.01	65.56	94.94	147.29	148.98	121.29
Minority Interest in Earnings	5.53	5.53	14.37	1.16	-	-
Net Income	90.53	71.08	109.31	148.44	148.98	121.29
Net Income to Common	90.53	71.08	109.31	148.44	148.98	121.29
Net Income Growth	19.71%	-34.97%	-26.36%	-0.36%	22.82%	-8.74%
Shares Outstanding (Basic)	12	13	13	13	12	12
Shares Outstanding (Diluted)	12	13	13	13	12	12
Shares Change (YoY)	-15.53%	0.44%	0.07%	3.56%	-	0.56%
EPS (Basic)	7.45	5.59	8.63	11.73	12.19	9.93
EPS (Diluted)	7.45	5.59	8.63	11.73	12.19	9.93
EPS Growth	41.72%	-35.25%	-26.41%	-3.78%	22.82%	-9.24%
Free Cash Flow	-151.89	-103.47	-130.31	-128.94	-44.99	-51.94
Free Cash Flow Per Share	-12.50	-8.14	-10.29	-10.19	-3.68	-4.25
Dividend Per Share	1.000	1.000	1.000	1.000	1.000	1.000
Dividend Growth	-	-	-	-	-	100.00%
Gross Margin	50.68%	48.38%	47.52%	47.86%	53.04%	36.93%
Operating Margin	7.94%	7.04%	8.51%	12.52%	15.50%	14.93%
Profit Margin	5.33%	4.24%	6.10%	10.54%	12.90%	10.76%
Free Cash Flow Margin	-8.94%	-6.18%	-7.27%	-9.15%	-3.90%	-4.61%
EBITDA	196.8	187.02	221.76	238.89	235.68	192.8
EBITDA Margin	11.58%	11.16%	12.37%	16.96%	20.41%	17.11%
D&A For EBITDA	61.91	69.1	69.19	62.56	56.72	24.55
EBIT	134.89	117.92	152.57	176.32	178.96	168.25
EBIT Margin	7.94%	7.04%	8.51%	12.52%	15.50%	14.93%
Effective Tax Rate	23.97%	33.65%	27.39%	13.59%	17.67%	26.01%
Revenue as Reported	1,712	1,688	1,816	1,433	1,172	1,135
Advertising Expenses	-	11.42	14.37	6.83	4.6	0.57

Source: S&P Global Market Intelligence. Standard template. Financial Sources.